These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2393 related items for PubMed ID: 24877633

  • 21. High-fat diets exaggerate endocrine and metabolic phenotypes in a rat model of DHEA-induced PCOS.
    Zhang H, Yi M, Zhang Y, Jin H, Zhang W, Yang J, Yan L, Li R, Zhao Y, Qiao J.
    Reproduction; 2016 Apr; 151(4):431-41. PubMed ID: 26814210
    [Abstract] [Full Text] [Related]

  • 22. Mouse models to study polycystic ovary syndrome: a possible link between metabolism and ovarian function?
    van Houten EL, Visser JA.
    Reprod Biol; 2014 Mar; 14(1):32-43. PubMed ID: 24607253
    [Abstract] [Full Text] [Related]

  • 23. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
    Li X, Hu S, Zhu Q, Yao G, Yao J, Li J, Wang Y, Ding Y, Qi J, Xu R, Zhao H, Zhu Z, Du Y, Sun K, Sun Y.
    Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
    [Abstract] [Full Text] [Related]

  • 24. Neurokinin 3 Receptor Antagonism Ameliorates Key Metabolic Features in a Hyperandrogenic PCOS Mouse Model.
    Sucquart IE, Nagarkar R, Edwards MC, Rodriguez Paris V, Aflatounian A, Bertoldo MJ, Campbell RE, Gilchrist RB, Begg DP, Handelsman DJ, Padmanabhan V, Anderson RA, Walters KA.
    Endocrinology; 2021 May 01; 162(5):. PubMed ID: 33522579
    [Abstract] [Full Text] [Related]

  • 25. Removal of DHT can relieve polycystic ovarian but not metabolic abnormalities in DHT-induced hyperandrogenism in mice.
    Sun LF, Yang YL, Xiao TX, Li MX, Zhang JV.
    Reprod Fertil Dev; 2019 Sep 01; 31(10):1597-1606. PubMed ID: 31142430
    [Abstract] [Full Text] [Related]

  • 26. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H, Tanir HM, Yildiz Z.
    Arch Gynecol Obstet; 2006 Jul 01; 274(4):227-32. PubMed ID: 16691383
    [Abstract] [Full Text] [Related]

  • 27. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
    Shi D, Dyck MK, Uwiera RR, Russell JC, Proctor SD, Vine DF.
    Endocrinology; 2009 Sep 01; 150(9):4425-36. PubMed ID: 19470707
    [Abstract] [Full Text] [Related]

  • 28. Dehydroepiandrosterone with a high-fat diet treatment at inducing polycystic ovary syndrome in rat model.
    He Y, Li X, Li Y, Kuai D, Zhang H, Wang Y, Tian W.
    Steroids; 2024 Jun 01; 206():109424. PubMed ID: 38642598
    [Abstract] [Full Text] [Related]

  • 29. MicroRNA-21 modulates brown adipose tissue adipogenesis and thermogenesis in a mouse model of polycystic ovary syndrome.
    Rezq S, Huffman AM, Basnet J, Alsemeh AE, do Carmo JM, Yanes Cardozo LL, Romero DG.
    Biol Sex Differ; 2024 Jul 10; 15(1):53. PubMed ID: 38987854
    [Abstract] [Full Text] [Related]

  • 30. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug 10; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 31. Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.
    Abbott DH, Dumesic DA, Levine JE.
    Expert Rev Endocrinol Metab; 2019 Mar 10; 14(2):131-143. PubMed ID: 30767580
    [Abstract] [Full Text] [Related]

  • 32. A Hyperandrogenic Environment Causes Intrinsic Defects That Are Detrimental to Follicular Dynamics in a PCOS Mouse Model.
    Bertoldo MJ, Caldwell ASL, Riepsamen AH, Lin D, Gonzalez MB, Robker RL, Ledger WL, Gilchrist RB, Handelsman DJ, Walters KA.
    Endocrinology; 2019 Mar 01; 160(3):699-715. PubMed ID: 30657917
    [Abstract] [Full Text] [Related]

  • 33. Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated reactive oxygen species production in pregnant rats that mimic the clinical features of polycystic ovary syndrome.
    Zhang Y, Zhao W, Xu H, Hu M, Guo X, Jia W, Liu G, Li J, Cui P, Lager S, Sferruzzi-Perri AN, Li W, Wu XK, Han Y, Brännström M, Shao LR, Billig H.
    J Physiol; 2019 Aug 01; 597(15):3927-3950. PubMed ID: 31206177
    [Abstract] [Full Text] [Related]

  • 34. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.
    Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA.
    Fertil Steril; 2005 Aug 01; 84(2):413-9. PubMed ID: 16084883
    [Abstract] [Full Text] [Related]

  • 35. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG, Patchava S, Laing I.
    Panminerva Med; 2008 Dec 01; 50(4):267-78. PubMed ID: 19078868
    [Abstract] [Full Text] [Related]

  • 36. The effect of cinnamon on polycystic ovary syndrome in a mouse model.
    Dou L, Zheng Y, Li L, Gui X, Chen Y, Yu M, Guo Y.
    Reprod Biol Endocrinol; 2018 Oct 19; 16(1):99. PubMed ID: 30340496
    [Abstract] [Full Text] [Related]

  • 37. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome.
    Seow KM, Ting CH, Huang SW, Ho LT, Juan CC.
    Taiwan J Obstet Gynecol; 2018 Oct 19; 57(5):696-704. PubMed ID: 30342654
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL, Ehrmann DA.
    Endocr Rev; 2016 Oct 19; 37(5):467-520. PubMed ID: 27459230
    [Abstract] [Full Text] [Related]

  • 40. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model.
    Aflatounian A, Edwards MC, Rodriguez Paris V, Bertoldo MJ, Desai R, Gilchrist RB, Ledger WL, Handelsman DJ, Walters KA.
    J Endocrinol; 2020 Jun 19; 245(3):381-395. PubMed ID: 32229702
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 120.